Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme
Metrics: PDF 1339 views | HTML 1999 views | ?
Sabrina Heynckes1,5, Annette Gaebelein1,5, Gerrit Haaker1,5, Jürgen Grauvogel1,5, Pamela Franco1,5, Irina Mader2,5, Maria Stella Carro1,5, Marco Prinz3,4,5, Daniel Delev1,5, Oliver Schnell1,5,* and Dieter Henrik Heiland1,5,*
1Department of Neurosurgery, Medical Center, University of Freiburg, Freiburg, Germany
2Department of Neuroradiology, Medical Center, University of Freiburg, Freiburg, Germany
3BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany
4Institute of Neuropathology, Medical Center, University of Freiburg, Freiburg, Germany
5Faculty of Medicine, University of Freiburg, Freiburg, Germany
*These authors have contributed equally to this work
Dieter Henrik Heiland, email: [email protected]
Keywords: immune checkpoints, PD-L1, GBM, recurrent GBM
Received: May 13, 2017 Accepted: May 23, 2017 Published: June 28, 2017
The biology of recurrent glioblastoma multiforme (GBM) is a dynamic process influenced by selection pressure induced by different antitumoural therapies. The poor clinical outcome of tumours in the recurrent stage necessitates the development of effective therapeutic strategies. Checkpoint-inhibition (PD1/PD-L1 Inhibition) is a hallmark of immunotherapy being investigated in ongoing clinical trials. The purpose of this study was to analyse the PD-L1 expression in de-novo and recurrent glioblastoma multiforme and to explore associated genetic alterations and clinical traits. We show that PD-L1 expression was reduced in recurrent GBM in comparison to de-novo GBM. Additionally, patients who received an extended dose of temozolomide (TMZ) chemotherapy showed a significantly reduced level of PD-L1 expression in the recurrence stage compared to the corresponding de-novo tumour. Our findings may provide an explanation for potentially lower response to immunotherapy in the recurrent stage due to the reduced expression of the therapeutic target PD-L1.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.